ArticleMicroorganisms2021
Impact of Phage Therapy on Multidrug-Resistant
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Bacteriophage-mediated reduction of uropathogenicInfection and immunity · 2026Article
- Engineering bacteriophages for gut health: precision antimicrobials and beyond.Journal of nanobiotechnology · 2026Review
- The gut reservoir of carbapenem-resistant Enterobacterales: from dysbiosis and colonization to infection and decolonization, with a focus on patients with hematologic malignancies - a narrative review.Frontiers in cellular and infection microbiology · 2026Review
- Fluoroquinolone resistance without fluoroquinolone use; the genie is truly out of the bottle.Frontiers in microbiology · 2026Review
- Pedal effect: aerobic and facultative anaerobic Enterobacter hormaechei maintain the homeostasis of the house fly gut microbiota under different oxygen conditions.Parasites & vectors · 2025Article
- Bacteriophage-mediated reduction of uropathogenicbioRxiv : the preprint server for biology · 2025Article
- Engineered Phage-Guided Nanotherapeutic Systems for Precision Antibacterial Therapy: Hacking Bacterial Resistance Mechanisms.Pharmaceutics · 2025Review
- In silico genomic insights into bacteriophages infecting ESBL-producing Escherichia coli from human, animal, and environmental sources.BMC microbiology · 2025Article
- Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.Frontiers in antibiotics · 2025Review
- The gut microbiome as a major source of drug-resistant infections: emerging strategies to decolonize and target the gut reservoir.Frontiers in cellular and infection microbiology · 2025Review
- Beyond Antibiotics: Exploring the Potential of Bacteriophages and Phage Therapy.PHAGE (New Rochelle, N.Y.) · 2024Review
- Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections.Infectious disease reports · 2024Review
- Navigating Antibacterial Frontiers: A Panoramic Exploration of Antibacterial Landscapes, Resistance Mechanisms, and Emerging Therapeutic Strategies.ACS infectious diseases · 2024Review
- Knowing Our Enemy in the Antimicrobial Resistance Era: Dissecting the Molecular Basis of Bacterial Defense Systems.International journal of molecular sciences · 2024Review
- A newFrontiers in microbiology · 2024Article
- Efficacy of Different Encapsulation Techniques on the Viability and Stability of Diverse Phage under Simulated Gastric Conditions.Microorganisms · 2023Article
- Insights on Current Strategies to Decolonize the Gut from Multidrug-Resistant Bacteria: Pros and Cons.Antibiotics (Basel, Switzerland) · 2023Article
- Modulation of the Gut Microbiota to Control Antimicrobial Resistance (AMR)-A Narrative Review with a Focus on Faecal Microbiota Transplantation (FMT).Infectious disease reports · 2023Review
- β-Lactamase Genes without Limits.Microorganisms · 2023Article
- Decolonization of asymptomatic carriage of multi-drug resistant bacteria by bacteriophages?Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
introductionThe growing resistance of bacteria to antibiotics is a major global public health concern. An important reservoir of this resistance is the gut microbiota. However, limited data are available on the ability of phage therapy to reduce the digestive carriage of multidrug-resistant bacteria. MATERIALS AND
methodsFour novel lytic phages were isolated in vitro for efficacy against an extended-spectrum beta-lactamase-producing (ESBL)
resultsThe two most intense models of digestive carriage were obtained by administering amoxicillin (0.5 g·L
conclusionsOral treatment with amoxicillin promoted digestive carriage in mice, which was also the case for the addition of pantoprazole. However, our study confirms the difficulty of achieving efficacy with phage therapy to reduce multidrug-resistant bacterial digestive carriage in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.